ABBV · 10-Q · 2026Q3 · Full report
Cash Flow and Capital Allocation
AbbVie Inc. · 2026-11-03 · Importance 49 · Surprise 32 · From source text
Operating cash flow for the first nine months of 2026 was $14.871 billion, up from $13.812 billion in 2025, reflecting higher operating results and lower litigation payments, partly offset by working-capital timing and higher contingent-consideration payments. Capital expenditures were $888 million, compared with $885 million in the prior-year period. AbbVie paid $9.2 billion in dividends, up from $8.7 billion, and repurchased 5 million shares for $1.1 billion, compared with 3 million shares for $606 million in 2025. The board raised the quarterly dividend from $1.73 to $1.82 per share beginning with the payment scheduled for February 16, 2027.
Key facts
- AbbVie repurchased 5 million shares for $1.1 billion in the nine months ended September 30, 2026, compared with 3 million shares for $606 million in the same 2025 period. source
- On October 30, 2026, AbbVie announced an increase in its quarterly dividend from $1.73 to $1.82 per share beginning with the dividend payable February 16, 2027, to stockholders of record January 15, 2027. source
- Investing cash flows for the nine months ended September 30, 2026 included $10.6 billion of net business-acquisition payments, primarily for Apogee, $1.4 billion of net payments for other acquisitions and investments, and $888 million of capital expenditures. source
- Operating cash flows for the nine months ended September 30, 2026 were $14.871 billion, compared with $13.812 billion in 2025. source
- AbbVie paid cash dividends of $9.2 billion in the nine months ended September 30, 2026, compared with $8.7 billion in the same 2025 period; the increase primarily reflected a higher quarterly dividend rate. source
- On September 10, 2026, AbbVie declared a quarterly dividend of $1.73 per share, payable November 16, 2026 to stockholders of record October 15, 2026. source
- Investing cash flows for the nine months ended September 30, 2026 included $1.1 billion primarily from the sale of investment securities acquired as part of the Apogee acquisition. source
- Operating cash flows increased in the nine months ended September 30, 2026, primarily due to higher operating results from revenue growth and lower litigation payments, partly offset by working-capital timing and higher contingent-consideration payments. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -7.2% | Investing cash flows for the nine months ended September 30, 2026 included $10.6 billion of net business-acquisition payments, primarily… |
| cash | negative | realized | -0.9% | Investing cash flows for the nine months ended September 30, 2026 included $10.6 billion of net business-acquisition payments, primarily… |
| cash | positive | realized | +0.7% | Operating cash flows for the nine months ended September 30, 2026 were $14.871 billion, compared with $13.812 billion in 2025. |
| cash | negative | realized | -0.6% | Investing cash flows for the nine months ended September 30, 2026 included $10.6 billion of net business-acquisition payments, primarily… |
| cash | negative | realized | -0.3% | AbbVie repurchased 5 million shares for $1.1 billion in the nine months ended September 30, 2026, compared with 3 million shares for $606… |
| cash | negative | committed | — | On October 30, 2026, AbbVie announced an increase in its quarterly dividend from $1.73 to $1.82 per share beginning with the dividend… |
| liability | negative | realized | — | On September 10, 2026, AbbVie declared a quarterly dividend of $1.73 per share, payable November 16, 2026 to stockholders of record… |
| cash | negative | committed | — | On September 10, 2026, AbbVie declared a quarterly dividend of $1.73 per share, payable November 16, 2026 to stockholders of record… |